DocDollars

Travere Therapeutics, Inc.

CA · United States · Reporting entity ID 100000061305

Total reported 2019–2025
$53.7M
#166 of 2,960 reporting companies — 0.1% of all reported industry payments
$10.8M in general payments across 85,270 records, plus $42.9M in research funding across 11,296 records.

How it breaks down

General payments $10,764,476
Research funding $42,946,645

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Travere Therapeutics, Inc. reported $53.7M to US doctors and teaching hospitals from 2019 to 2025, ranking #166 of 2,960 reporting companies. 80% of that was research funding and 20% general payments such as consulting, speaking, food and travel. 85,270 general payment records and 11,296 research records were filed.

Common questions about Travere Therapeutics, Inc.

How much has Travere Therapeutics, Inc. paid US doctors?

Travere Therapeutics, Inc. reported $53,711,121 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $10,764,476 in general payments, $42,946,645 in research funding.

How does Travere Therapeutics, Inc. rank among drug and device companies?

It ranks #166 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Travere Therapeutics, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.